The Evolution of Liver Fibrosis in Patients with Viral C Infection Post Oral Antiviral Treatment

Oana Irina Gavril; Radu Sebastian Gavril Florin Mitu

doi:10.2478/inmed-2022-0197

.blurhash-client-img { display: none !important; }

The Evolution of Liver Fibrosis in Patients with Viral C Infection Post Oral Antiviral Treatment

Internal Medicine

Volume 19 (2022): Issue 1 (January 2022)

By: Oana Irina Gavril and Radu Sebastian Gavril Florin Mitu

Open Access

|Apr 2022

Abstract

Hepatitis C virus infection has been for several decades the major cause of cirrhosis and its complications worldwide. However, an arsenal of new and highly effective oral direct-acting antiviral drugs has changed the course of HCV treatment. The effects of HCV elimination are broad and include an overall reduction in mortality in patients with advanced fibrosis, a reduction of the risk of HCC in patients with advanced fibrosis and a reduction in extrahepatic manifestations including HCV-related non-Hodgkin’s lymphoma, other lymphoproliferative disorders and cryoglobulinemic vasculitis. Fibrosis regression is associated with a broad clinical benefit and remains an important therapeutic target in HCV patients who have obtained RSV.

References

1. Li J, Tuo B. Current and Emerging Approaches for Hepatic Fibrosis Treatment. Gastroenterol Res Pract. 2021 Jul 16;2021:6612892. doi: 10.1155/2021/6612892. PMID: 34326871; PMCID: PMC8310447.10.1155/2021/6612892831044734326871
Search in Google Scholar Back to article
2. Popov Y, Sverdlov DY, Sharma AK, et al. Tissue transglutaminase does not affect fibrotic matrix stability or regression of liver fibrosis in mice. Gastroenterology 2011;140:1642–1652.10.1053/j.gastro.2011.01.040337413221277850
Search in Google Scholar Back to article
3. Rockey DC, Bell PD, Hill JA. Fibrosis–a common pathway to organ injury and failure. N Engl J Med 2015; 372:1138–1149.10.1056/NEJMra130057525785971
Search in Google Scholar Back to article
4. Massard J, Ratziu V, Thabut D, et al. Natural history and predictors of disease severity in chronic hepatitis C. J Hepatol 2006;44:S19–S24.10.1016/j.jhep.2005.11.00916356583
Search in Google Scholar Back to article
5. Eslam M, McLeod D, Kelaeng KS, et al. IFN-lambda3, not IFN-lambda4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis. Nat Genet 2017;49:795–800.10.1038/ng.383628394349
Search in Google Scholar Back to article
6. Popov Y, Sverdlov DY, Bhaskar KR, et al. Macrophagemediated phagocytosis of apoptotic cholangiocytes contributes to reversal of experimental biliary fibrosis. Am J Physiol 2010;298:G323–G334.10.1152/ajpgi.00394.2009283851620056896
Search in Google Scholar Back to article
7. Chen SH, Huang CL, Chiang IP, et al. Liver fibrosis regression correlates with downregulation in liver angiogenesis in chronic hepatitis C through viral eradication, European Journal of Gastroenterology & Hepatology: September 2021 - Volume 33 - Issue 9 - p 1209-1217.10.1097/MEG.000000000000183332658008
Search in Google Scholar Back to article
8. Wanless IR, Nakashima E, Sherman M. Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med 2000;124:1599–1607.10.5858/2000-124-1599-ROHC11079009
Search in Google Scholar Back to article
9. Lee YA, Friedman SL. Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C? Antiviral Res 2014;107:23–30.
Search in Google Scholar Back to article
10. Goodman ZD, Stoddard AM, Bonkovsky HL, et al. Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trial. Hepatology 2009;50:1738–1749.10.1002/hep.23211370763319824074
Search in Google Scholar Back to article
11. Brian L. Pearlman1,3,4 and Nomi Traub. Sustained Virologic Response to Antiviral Therapy for Chronic Hepatitis C Virus Infection: A Cure and So Much More. Sustained Virologic Response Hepatitis C d CID 2011:52 (1 April) d 889-90010.1093/cid/cir07621427396
Search in Google Scholar Back to article
12. Knop V, Hoppe D, Welzel T, et al. Regression of fibrosis and portal hypertension in HCV-associated cirrhosis and sustained virologic response after interferon-free antiviral therapy. J Viral Hepat 2016;23:994–1002.10.1111/jvh.1257827500382
Search in Google Scholar Back to article
13. Poynard T, Moussalli J, Munteanu M, et al. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C. J Hepatol 2013;59:675–683.10.1016/j.jhep.2013.05.01523712051
Search in Google Scholar Back to article
14. Lu M, Li J, Zhang T, et al. Serum biomarkers indicate long-term reduction in liver fibrosis in patients with sustained virological response to treatment for HCV infection. Clin Gastroenterol Hepatol 2016;14: 1044–1055.e3.10.1016/j.cgh.2016.01.009572625026804385
Search in Google Scholar Back to article
15. Dhanasekaran R, Sanchez W, Mounajjed T, et al. Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence. Liver Int 2015;35:2433–2441.10.1111/liv.1289026058570
Search in Google Scholar Back to article
16. Mauro E, Crespo G, Montironi C, et al. Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C. Hepatology 2018;67:1683–1694.10.1002/hep.2955728960366
Search in Google Scholar Back to article
17. Rockey DC, Bissell DM. Noninvasive measures of liver fibrosis. Hepatology 2006;43:S113–S120.10.1002/hep.2104616447288
Search in Google Scholar Back to article
18. Rockey DC. Noninvasive assessment of liver fibrosis and portal hypertension with transient elastography. Gastroenterology 2008;134:8–14.10.1053/j.gastro.2007.11.05318166342
Search in Google Scholar Back to article
19. Van der Meer AJ, Feld JJ, Hofer H, et al. Risk of cirrhosis related complications in patients with advanced fibrosis following hepatitis C virus eradication. J Hepatol 2017; 66:485–493.10.1016/j.jhep.2016.10.01727780714
Search in Google Scholar Back to article
20. Nahon P, Bourcier V, Layese R, et al. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology 2017;152:142–156.e2.
Search in Google Scholar Back to article
21. Rossi C, Jeong D, Wong S, et al. Sustained virological response from interferon-based hepatitis C regimens is associated with reduced risk of extrahepatic manifestations. J Hepatol 2019;71:1116–1125.10.1016/j.jhep.2019.07.02131433302
Search in Google Scholar Back to article
22. Hill LA, Delmonte RJ, Andrews B, et al. Treatment of hepatitis C with direct-acting antivirals significantly reduces liver-related hospitalizations in patients with cirrhosis. Eur J Gastroenterol Hepatol 2018;30:1378–1383.10.1097/MEG.000000000000119529975243
Search in Google Scholar Back to article
23. Sun YM, Chen SY, You H. Regression of liver fibrosis: evidence and challenges. Chin Med J (Engl). 2020;133(14):1696-1702.10.1097/CM9.0000000000000835740174132568866
Search in Google Scholar Back to article

Articles in this issue

DOI: https://doi.org/10.2478/inmed-2022-0197 | Journal eISSN: 1220-5818 | Journal ISSN: 1220-5818

Journal RSS Feed

Language: English

Page range: 53 - 59

Published on: Apr 10, 2022

Published by: Romanian Society of Internal Medicine

In partnership with: Paradigm Publishing Services

Publication frequency: 4 issues per year

Keywords:

hepatitis C virus,

fibrosis,

cirrhosis,

oral direct-acting antiviral drugs

Related subjects:

Medicine,

Clinical medicine,

Internal medicine,

Internal medicine, other,

Cardiology,

Gastroenterology,

Pneumology

© 2022 Oana Irina Gavril, Radu Sebastian Gavril Florin Mitu, published by Romanian Society of Internal Medicine
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Volume 19 (2022): Issue 1 (January 2022)